ClinicalTrials.gg
Active, not recruitingNCT05846893REVERSEUpdated May 28, 2026

Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease

An interventional study of SeQuent® Please NEO drug-coated balloon catheter and Current-generation drug-eluting stent in Coronary Artery Disease, Myocardial Ischemia and Acute Coronary Syndrome, sponsored by B. Braun Medical Industries Sdn. Bhd.. Active, not recruiting at 21 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by B. Braun Medical Industries Sdn. Bhd. (part of B. Braun) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,436
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Coronary Artery Disease by B. Braun — 1 open to participants now, 3 under way, none of them phase 3. Coronary Artery Disease · B. Braun.

Started
2023
the only one that year
No phase
4 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Coronary Artery Disease by B. Braun, this one is the only one that started in 2023, is one of 4 with no phase, and was the 10th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 11 studies in Coronary Artery Disease by B. Braun is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Coronary Artery Disease by B. Braun, or all of them as a file.
02

Study summary

Prospective, randomised, open-label, international multicenter trial to evaluate the safety and efficacy of drug-coated balloon (DCB) treatment compared to drug-eluting stenting (DES) in patients with large coronary artery disease.

Read the detailed description

Although several reports suggested that DCB application was safe for larger coronary artery lesions and showed good long-term outcomes, there is limited randomised controlled trial (RCT) data on the safety and efficacy of DCB in large coronary artery disease.

Therefore, the study aims to demonstrate the non-inferiority of the drug-coated balloon (DCB) treatment against current-generation drug-eluting stenting (DES) in patients with de novo lesions in large coronary artery disease (reference vessel diameter ≥3.0 mm by visual estimation).

The hypothesis of the study is the clinical outcomes of patients treated with DCB are non-inferior to those treated with current-generation DES.

03

Conditions studied

  • Coronary Artery Disease
  • Myocardial Ischemia
  • Acute Coronary Syndrome
  • Coronary Stenosis
  • De Novo Stenosis

Keywords

  • de novo
  • large vessel
  • coronary artery disease
  • cardiovascular disease
  • coronary occlusion
  • heart disease
  • acute coronary syndrome
  • angina
  • ischemia
  • stenosis
  • percutaneous coronary intervention
  • angioplasty
  • drug-coated balloon
  • drug-eluting stent
  • SeQuent Please
  • randomised trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient-related:

    1. Patient must be ≥ 18 years of age
    2. Patient is able to verbally confirm understanding of the study aim, risks, benefits, and treatment alternatives of receiving DCB or DES and he/she or his/her legally authorized representative provides written prior to any study-related procedure
    3. (i) Clinical evidence of angina, and/or (ii) an abnormal functional study demonstrating myocardial ischemia due to the target lesion(s), or (iii) acute coronary syndrome [unstable angina or non-ST-elevation myocardial infarction (NSTEMI) or uneventful STEMI (≥ 48 hours after primary PCI and no sign of thrombus in lesion(s) to treat)]
    4. Patient with lesions suitable for PCI with a DCB (and/or DES) according to the Instructions for Use
    5. Patient is able to comply with the study protocol and agrees to undergo the clinical follow-up of 30 days, 6 months, 12 months, 24 months, and 36 months
  • Lesion-related:

    1. Presence of significant de novo large vessel coronary artery disease (reference vessel diameter ≥3.0 mm by visual estimation) with either ≥ 70% diameter stenosis or intermediate ≥ 50% to \<70% diameter stenosis with abnormal functional test or symptom of ischemia
    2. Successful lesion preparation. For randomisation, the lesion must satisfy the following criteria after optimal balloon angioplasty: no flow-limiting dissection (TIMI=3), and residual stenosis is ≤ 30%
  • Multivessel disease with two or more vessels showing diameter stenosis of 50% or more is not an exclusion as long as it fulfills all study's eligibility criteria.
  • In diffuse lesion, inclusion is possible if the proximal reference vessel diameter is 3.0 mm or more.

Exclusion criteria

Exclusion Criteria:

  • Patient-related:

    1. Intolerance or allergy to Paclitaxel and/or the delivery matrix (main ingredient: Iopromide)
    2. Severe allergy to contrast media
    3. Recent STEMI (ongoing or \< 48 hours after primary PCI and/or has sign of thrombus in lesion(s) to treat)
    4. NSTEMI hemodynamically unstable
    5. Known of \<30%
    6. Inability to take dual antiplatelet therapy or anticoagulation, or single antiplatelet therapy for at least six months
    7. Non-cardiac co-morbid conditions that may result in protocol non-compliance and inability of patient to complete the study (per the site investigator's medical judgment)
    8. Patient with concomitant medical illnesses that require cytostatic, radiation therapy or renal replacement therapy
    9. Patient who is currently/ planning to participate in another clinical trial when such participation could confound the treatment or outcomes of this study, except for observational registry
    10. Pregnancy or lactation
    11. Patient under administrative or judicial custody
  • Lesion-related:

    1. Small vessel disease, defined as \<3.0 mm of reference vessel diameter by visual estimation
    2. In-stent restenosis lesions for study lesions
    3. Patient will be excluded if meet any of the following angiographic exclusion criteria after lesion preparation:

      (i) Flow limiting dissection with TIMI flow \< III (ii) Residual diameter stenosis >30%

      * The case of persistent ischemic symptoms/signs is up to the operator's decision

    4. Lesions which are untreatable with PCI or other interventional techniques and coronary artery spasm in the absence of a significant stenosis
    5. Left main disease or aorta-ostial lesion requiring revascularization
    6. Severely calcified or tortuous vessels precluding DCB or DES application
    7. Prior Coronary Artery Bypass Graft (CABG)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,436 participants (estimated)

Study arms

  • Experimental
    SeQuent® Please NEO drug-coated balloon catheter

    Device: SeQuent® Please NEO drug-coated balloon catheter

  • Experimental
    Current-generation drug-eluting stent

    Device: Current-generation drug-eluting stent

Interventions

  • DeviceSeQuent® Please NEO drug-coated balloon catheter

    Treatment of coronary artery disease with SeQuent® Please NEO for de novo lesions in native large coronary arteries

  • DeviceCurrent-generation drug-eluting stent

    Treatment of coronary artery disease with current-generation drug-eluting stent for de novo lesions in native large coronary arteries

06

What researchers measure

Primary outcomes

  1. Net Adverse Clinical Event (NACE)

    Net adverse clinical event (NACE): a composite of all-cause death, non-fatal myocardial infarction, clinically driven target vessel revascularization, or major bleeding (BARC type 3 to 5)

    Time frame: At 1 year

Secondary outcomes

  1. All-cause death

    Time frame: At 12, 24, and 36 months

  2. Non-fatal myocardial infarction

    Time frame: At 12, 24, and 36 months

  3. Clinically driven target vessel revascularization

    Time frame: At 12, 24, and 36 months

  4. Major bleeding (BARC type 3 to 5)

    Time frame: At 12, 24, and 36 months

  5. Cardiac death

    Time frame: At 12, 24, and 36 months

  6. Target vessel myocardial infarction

    Time frame: At 12, 24, and 36 months

  7. Periprocedural myocardial infarction

    Time frame: At 12, 24, and 36 months

  8. Target lesion revascularization

    Time frame: At 12, 24, and 36 months

  9. Stent/lesion thrombosis in treated lesion defined according to the Academic Research Consortium-2 (ARC-2) criteria

    Time frame: At 12, 24, and 36 months

  10. Rehospitalization related to study endpoints

    Rate of hospitalization related to study endpoints

    Time frame: At 30 days, 12 months, 24 months, and 36 months

  11. Stroke (ischemic and hemorrhagic)

    Number of participants with stroke (ischemic and hemorrhagic)

    Time frame: At 12, 24, and 36 months

  12. Total angioplasty procedure time

    Time frame: During the index procedure

  13. Fluoroscopy time of the angioplasty procedure

    Time frame: During the index procedure

  14. Contrast volume of the angioplasty procedure

    Time frame: During the index procedure

  15. Number of devices (DCB/ DES) used for PCI treatment

    Time frame: During the index procedure

Other outcomes

  1. Late lumen loss (LLL)

    LLL is defined as: the minimal lumen diameter (MLD) immediately after PCI minus the MLD at the follow-up.

    Time frame: At 9-12 months post-procedure

  2. Percentage of diameter stenosis

    Time frame: At 9-12 months post-procedure

  3. Minimal lumen diameter

    Time frame: At 9-12 months post-procedure

  4. Binary restenosis

    Time frame: At 9-12 months post-procedure

  5. Quality of life analysis

    Quality of life analysis using EQ-5D-5L questionnaire

    Time frame: After 12, 24, and 36 months

  6. Incidence of angina

    Time frame: At baseline and 12 months

  7. Dual Antiplatelet Therapy (DAPT) duration

    Time frame: At 30 days, 6 months, and 12 months

  8. Comparison of NACE between DCB vs. DES in sex difference, diabetes mellitus, and multivessel disease patients

    Time frame: At 1 year

07

Study locations

21 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for May 2027, 44 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 44 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2023
First posted
May 6, 2023
StartActual
Sep 7, 2023
Primary completionEst.
May 2027
CompletionEst.
Jan 2029
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05846893
Collaborators
B. Braun Melsungen AG, Ulsan University Hospital, European Cardiovascular Research Center, Seoul National University Hospital, Universität des Saarlandes
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Sep 7, 2023
Primary completion
May 2027 (estimated)
Completion
Jan 2029 (estimated)
Last update
May 28, 2026

Study contacts

Eun-Seok Shin, MD, Ph.D
study chair · Ulsan University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion